Evidence map›Paper›PMID 25798946›Full record

ArticlePloS one2015

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.

Molly H Jenkins, Constance E Brinckerhoff, David W Mullins

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Significance of 5-International journal of molecular sciences · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness.Journal of experimental & clinical cancer research : CR · 2018
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. CXCR3Scientific reports · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Molly H JenkinsDepartment of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.
Constance E BrinckerhoffDepartment of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America; Department of Biochemistry, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.
David W MullinsDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
IMMUNOBIOLOGY OF MYELOID AND LYMPHOID CELLST32AI007363 · NIAID · DARTMOUTH COLLEGE · PI Claudia V Jakubzick · 1990 to 2026
$9.5M
Cancer Biology and Molecular TherapeuticsT32CA009658 · NCI · DARTMOUTH COLLEGE · PI EASTMAN, ALAN R · 1991 to 2011
$3.8M
Role of CXCR3 for CD8+ T cells in cancer immunotherapyR01CA134799 · NCI · UNIVERSITY OF VIRGINIA · PI MULLINS, DAVID W. · 2009 to 2013
$1.6M
NCI NIH HHS CA009658NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA134799NCI NIH HHS R01CA134799NCI NIH HHS T32 CA009658NIAID NIH HHS AI007363NIAID NIH HHS T32 AI007363
6 · The paper itself

Abstract

unlabelledPatients with early stage, radial growth phase (RGP) melanoma have a 97% survival rate; however, when the melanoma progresses to the invasive vertical growth phase (VGP), survival rates decrease to 15%. The targets of many clinical trials are the known genetic and molecular mechanisms involved in melanoma progression, with the most common oncogenic mutation being the BRAFV600E. However, less than half of melanomas harbor this mutation, and consequently, do not respond to the current BRAF targeted treatments. It is therefore critical to elucidate alternative mechanisms regulating melanoma progression. Increased expression of the chemokine receptor, CXCR3, on melanoma cells is correlated with increased metastasis and poor patient outcomes, suggesting a role for CXCR3 in the RGP to VGP transition. We found that endogenous CXCR3 can be induced in two RGP cell lines, BOWES (BRAFWT) and WM35 (BRAFV600E), with in vitro environmental stress and nutrient deprivation. Signaling via induced endogenous CXCR3 is linked with IL-8 expression in BOWES cells. Ectopic overexpression of CXCR3 in BOWES cells leads to increased ligand-mediated phERK, cellular migration, and IL-8 expression in vitro, and to increased tumorigenesis and lymph node metastasis in vivo. Our results demonstrate that, in BRAFWT melanomas, CXCR3 signaling mediates significant increases in IL-8 expression, suggesting that CXCR3 expression and signaling may represent a transformative event that drives the progression of BRAFWT melanomas. IMPLICATIONS: Expression of CXCR3 on BRAFWT melanoma cells may be a mediator of melanoma progression.

Indexed as

Signal TransductionAnimalsCarcinogenesisCell Line, TumorHumansInterleukin-8MaleMelanomaMiceMice, Inbred NODMice, SCIDProto-Oncogene Proteins B-rafReceptors, CXCR3Interleukin-8Proto-Oncogene Proteins B-rafReceptors, CXCR3

Identifiers

PMID25798946
PMCPMC4370421
OpenAlexW2024303655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.